Science Education
>

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Instructor Prep
concepts
Student Protocol
JoVE 杂志
免疫与感染
Author Produced
需要订阅 JoVE 才能查看此.  登录或开始免费试用。
JoVE 杂志 免疫与感染
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

The procedures used in this study were approved by the Ethics Committee on the Use of Animals of the Oswaldo Cruz Foundation (CEUA licenses n°002-08, 36/10 and 054/2015). Male Swiss Webster mice weighing between 20-30 g, provided by the Institute of Science and Technology in Biomodels (ICTB) of the Oswaldo Cruz Foundation (FIOCRUZ), were used for the experiments. The animals were kept in ventilated isolators in the Pavilhão Ozório de Almeida's vivarium, and water and food were available ad libitum. They were exposed to a 12 h/12 h light and dark cycle. 

1. Preparation of sodium oleate solution

  1. Use oleic acid to prepare a 100 mmol/L of sodium oleate stock solution in any sterile tube or glass flask.
    NOTE: A 50 mL (final volume) solution was prepared for the present work, but the volume must be adjusted as per the experimental need. The solution must be always prepared in sterile tubes or glass containers.
    1. First, add NaOH tablets or solution in ultrapure water to elevate the pH. A pH value of 12-13 is recommended for a 25 mL volume.
      NOTE: Alternatively, Tris base can be used to prepare the Tris-oleate solution.
    2. Add the oleic acid (see Table of Materials) very slowly, drop by drop, under constant agitation in an ultrasonic bath at 37 °C.
      NOTE: If oleic acid precipitation occurs, start all over from the beginning.
    3. Once oleic acid is completely dissolved, carefully adjust the pH to 7.4, drop by drop under stirring, with ultra-pure diluted HCl and then adjust to the final volume of 50 mL.
      ​NOTE: Freshly prepare the working oleate solutions. Alternatively, the solution may be aliquoted, stocked, and maintained at -20 °C in a nitrogen-enriched environment to avoid oxidation for no longer than a month. Avoid frozen-refrozen cycles.

2. Induction of lung injury by oleic acid

  1. Perform the intratracheal administration of oleic acid.
    1. Anesthetize the mice using 5% isoflurane with 2 L/min of O2 employing a veterinary anesthetic vaporizer (Figure 1A). Remove the fur at the incision area with depilatory cream and disinfect the area with three alternating rounds of betadine scrub and alcohol using sterile gauze. Confirm the depth of anesthesia by toe pinch.
      NOTE: Use sterile gloves and instruments during the procedure. Use a drape to cover the animal and expose only the incision site. Perform the experiment in a biological safety cabinet to avoid isofluorane escape to the environment. Analgesics are not administered as they may inhibit the inflammatory response.
    2. After anesthesia, lay the animal in a dorsal decubitus position and make an incision (0.5-1 cm) in V-shape at the thyroid level. Gently displace the thyroid to expose the trachea (Figure 1B) and inject 50 µL of the prepared oleate solution (step 1).
      NOTE: The mice were divided into two groups, with eight animals in each group. The lung injury group receives sodium-oleate solution at 25 mM (1.25 µmol), and the control group receives 50 µL of sterile saline by instillation into the trachea of each mouse with an insulin syringe (volume 300 µL, 30 G) (Figure 1C).
    3. Suture the mice's incision site with a synthetic non-absorbable monofilament suture, return it to their cage, and monitor it until complete recovery from the surgery. During all procedures, maintain the animals on a heating pad at 37 °C.
      NOTE: Mice usually take up to 15 min to recover from surgery.
  2. Perform intravenous administration of oleic acid.
    1. After anesthesia (step 2.1.1, Figure 2A), inject intravenously into the orbital plexus by inserting the ultrafine needle (see Table of Materials) in the medial canthus of the eye socket (Figure 2B).
      ​NOTE: The mice were divided into two groups, with eight animals in each group. Each group receives 100 µL of the sodium-oleate solution at 10 µmol of OA per animal, while the control group receives 100 µL of sterile saline.
  3. After the surgery, monitor the animals daily for adverse reactions. Humane endpoints for euthanasia include adverse reactions, convulsions, and coma.

3. Bronchoalveolar lavage fluid collection (BALF)

  1. Euthanize the mice with an intraperitoneal lethal dose of ketamine (300 mg/Kg) and xylazine (30 mg/Kg) (see Table of Materials).
  2. Lay the animal in the dorsal decubitus position, make an incision of approximately 1 cm with surgical scissors in the animals' anterior region, expose the trachea and make a small cut to introduce an intravenous catheter (20 G).
  3. Connect the catheter to a 1 mL sterile syringe, slowly and gradually inject 0.5 mL of sterile saline into the lungs, and then aspirate the fluid from the BALF with the same syringe. Repeat it 3-5 times, and transfer it to a sterile microtube, placing them in ice.
    ​NOTE: The samples can be stored at -20 °C for up to 6 months.

4. Total and differential cell analysis in BALF

  1. For total cell count, dilute 20 µL of BALF in 180 µL (10x dilution) of Turk's solution (see Table of Materials). Perform the counting using a Neubauer chamber under an optical microscope with a 40x objective.
  2. For differential count, put 100 µL of BALF in the cellular funnel containing slides and centrifuge it at 22.86 x g for 5 min at 4 °C in a cytocentrifuge, and stain with May-Grunwald (15%, pH 7.2)-Giemsa (1:10) (see Table of Materials). Proceed with cell count in a light microscope with immersion objective.

5. Determination of total protein in BALF

  1. Determine the total BALF supernatant protein by a commercial protein quantification kit and read the absorbance at 562 nm using a spectrophotometer following the manufacturer's instructions (see Table of Materials).

6. Enzyme immunosorbent assays

  1. Centrifuge BALF at 1,200 x g for 10 min at 4 °C. Then collect the supernatant with a pipette and store it at -80 °C for assays of TNF-α, IL-1β, IL-6, and PGE215,23,25.
    NOTE: The centrifugation in step 6.1 makes the BALF cell-free.
    1. Perform the cytokines assays on cell-free BALF using a commercial ELISA kit according to the manufacturer's instructions. Carry out the PGE2 assay using an enzyme immunoassay (EIA) kit following the manufacturer's instructions (see Table of Materials).

7. Lipid body staining and counting

  1. Fix the leukocytes on cytospin slides using 3.7% formaldehyde in Ca2+, Mg2+ free Hank's buffered salt solution (HBSS, pH 7.4) and stain with 1.5% OsO4 while still moist3 (see Table of Materials). Then, count the lipid bodies per cell in 50 consecutive leukocytes from each slide using the oil-immersion objective lens of the microscope.

8. Statistical analysis

  1. Perform statistical analysis using graphing and statistics software (see Table of Materials). Express the results as mean ± SEM and analyze by one-Way Anova followed by a post-test Newman-Keuls-Student26. Consider the differences significant when P < 0.05.

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Learning Objectives

In an uninjured lung, alveolar fluid clearance occurs by the transport of ions through the intact alveolar epithelial layer. The osmotic gradient carries fluid from the alveoli into the pulmonary interstitium, where it is drained by lymphatic vessels or reabsorbed. Na/K-ATPase drives this transport11. OA is an inhibitor of Na/K-ATPase27 and sodium channel21, which may contribute to edema formation, as we have already suggested23. The exacerbated inflammatory response in ARDS leads to alveolar damage, increased endothelial and epithelial permeability, and accumulation of alveolar fluid rich in protein and inflammatory cells, causing edema. The edema causes the lungs to increase breathing rate due to the accumulation of interstitial fluid and gas exchange impairment, resulting in hypoxemia and respiratory failure28. Cytokines such as TNF-α and vascular endothelial growth factor (VEGF) destabilize VE-cadherin bonds, contributing to increased endothelial permeability and alveolar fluid accumulation7.

OA injection increased total leukocytes in intratracheal and intravenous routes (Figure 3). It was necessary to induce OA for lung injury by the intravenous route rather than the intratracheal route. The present work showed an increase in neutrophil counts in BALF at 6 h, with the peak at 24 h and decreasing at 48 h and 72 h. A higher concentration of IL-6, IL-1β, and TNF-α in the BALF was observed after 24 h of OA intratracheal instillation23 (Figure 4). OA prevents edema clearance and can trigger the formation of edema rich in protein by both intravenous and intratracheal routes15,23. The lung edema was assessed by total protein assay in BALF, showing that i.v. and i.t. administration increased total protein concentration (Figure 5). Lipid bodies are intracellular organelles containing substrate and enzymes to eicosanoids production8,29. The formation of lipid bodies enhances the production of lipid mediators, and it can be used to access cell activation. Intratracheal and intravenous OA injection enhanced lipid bodies formation and PGE2 concentration23 after 24 h (Figure 6). OA injection also induced tissue disruption, hemorrhage, and leukocyte infiltration in intratracheal and intravenous routes, as shown in the hematoxylin and eosin (H&E) staining histology (Figure 7). Also, OA causes alteration in lung function19. Thus, oleic acid-induced lung injury presents numerous ARDS features.

Figure 1
Figure 1: The individual steps in the intratracheal administration protocol. (A) A mouse is anesthetized using 5% isofluorane and 2 L/min of O2. (B) A tracheal incision with a surgical scissor in mice in dorsal decubitus position. (C) Intratracheal instillation using an insulin syringe. Created with BioRender.com. Please click here to view a larger version of this figure.

Figure 2
Figure 2: The individual steps in the intravenous administration protocol. (A) A mouse is anesthetized with 5% isofluorane and 2L/min of O2. (B) Intravenous injection using an insulin syringe by the medial canthus. Created with BioRender.com. Please click here to view a larger version of this figure.

Figure 3
Figure 3: Administration of OA induces leukocyte activation in the BALF of mice. Total leukocytes in intravenous (i.v) and intratracheal administration (i.t) (A) and an illustrative photomicrograph (1000x magnification) in intratracheal administration (i.t.) stained with May-Grünwald-Giemsa (B) were performed 24 h after the OA challenge. Scale bar = 10 μm. The same volume of sterile saline was administered to the control group. Each bar represents the mean ± SEM of at least seven animals. *P < 0.05, compared to controls. Please click here to view a larger version of this figure.

Figure 4
Figure 4: Intratracheal administration (i.t) of OA induces the production of inflammatory mediators in the lung of mice. TNF-α (A), IL-6 (B), IL-1β (C) were measured 24 h after the challenge. Sterile saline was administered to the control group. Each bar represents the mean ± SEM for at least six animals. *P < 0.05, compared to controls. Please click here to view a larger version of this figure.

Figure 5
Figure 5: Total protein content in BALF 24 h after OA injection. Intratracheal (i.t.) and intravenous (i.v.) administration of OA increases total protein in the BALF of mice. The Control group received the same volume of sterile saline. The results are means ± SEM from at least six different animals. *P < 0.0001, compared to controls. Please click here to view a larger version of this figure.

Figure 6
Figure 6: Lipid body formation in leukocytes and PGE2 production in BALF of OA treated mice. Intratracheal (i.t) and intravenous (i.v) administration of OA induces inflammatory mediators and lipid bodies accumulation in the BALF of mice (A) and (B), respectively. (C) Illustrative photomicrograph of lipid bodies (1000x magnification) stained in the lungs of the animals with osmium tetroxide (OsO4) 24 h after OA challenge. The arrows point to the lipid bodies. Scale bar = 10 μm. Controls received the same volume of saline. The results are means ± SEM from seven animals. *P < 0.05, compared to controls. Please click here to view a larger version of this figure.

Figure 7
Figure 7: Illustrative pulmonary histology in mice. (A) Control mice treated with saline and no sign of hemorrhage. (B) Intravenous administration of OA (i.v). (C) Intratracheal administration (i.t) with tissue alterations. H&E staining was performed. Magnification, 1000x. Scale bar = 50 μm. Please click here to view a larger version of this figure.

List of Materials

Anesthetic vaporizer SurgiVet model 100
Braided slik thread with needle number 5 Shalon medical N/A
Cabinet vivarium Insight  Model EB273
Centrifuge Eppendorf 5430/5430R
Cytofunnel ThermoFisher 11-025-48
Drontal puppy Bayer N/A
Hank's balanced Salts Sigma-Aldrich H4981
Heatpad tkreprodução TK-500
Hydrocloric Acid Sigma-Aldrich 30721
Insulin syringe Ultrafine BD 328322
Isoforine 1mL/mL Cristália N/A
Ketamine Syntec N/A
May-Grunwald-Giemsa Sigma-Aldrich 205435
Micro BCA Protein Assay Kit ThermoFisher 23235
Microscope  PrimoStar Carl Zeiss
Mouse IL-1 beta duoSet ELISA R&D system DY401
Mouse IL-6 duoSet ELISA R&D system DY406
Mouse TNF-alpha duoSet ELISA R&D system DY410
Neubauer chamber improved bright-line Global optics
Oleic Acid (99%) Sigma-Aldrich O1008
Osmium tetroxide solution (4%) Sigma-Aldrich 75632
Peripheral Intravenous Catherter 20 G BD Angiocath 388333
Prism 8 (graphic and statistic software) Graphpad N/A
Prostaglandin E2 ELISA Kit -Monoclonal Cayman Chemical 514010
Shandon Cytospin 3 ThermoFisher N/A
Sodium hydroxide Merck 1,06,49,81,000
Spectrophotometer Molecular Devices SpectraMax ABS plus
Swiss webster mice ICTB/FIOCRUZ N/A
Syringe 1 mL BD 990189
Tris-base Bio Rad 161-0719 Electrophoresis purity reagent
Türk's solution Sigma-Aldrich 93770
Xilazine Syntec N/A

Lab Prep

Acute respiratory distress syndrome (ARDS) is a significant threat to critically ill patients with a high fatality rate. Pollutant exposure, cigarette smoke, infectious agents, and fatty acids can induce ARDS. Animal models can mimic the complex pathomechanism of the ARDS. However, each of them has limitations. Notably, oleic acid (OA) is increased in critically ill patients with harmful effects on the lung. OA can induce lung injury by emboli, disrupting tissue, altering pH, and impairing edema clearance. OA-induced lung injury model resembles various features of ARDS with endothelial injury, increased alveolar permeability, inflammation, membrane hyaline formation, and cell death. Herein, induction of lung injury is described by injecting OA (in salt form) directly into the lung and intravenously in a mouse since it is the physiological form of OA at pH 7. Thus, the injection of OA in the salt form is a helpful animal model to study lung injury/ARDS without causing emboli or altering the pH, thereby getting close to what is happening in critically ill patients.

Acute respiratory distress syndrome (ARDS) is a significant threat to critically ill patients with a high fatality rate. Pollutant exposure, cigarette smoke, infectious agents, and fatty acids can induce ARDS. Animal models can mimic the complex pathomechanism of the ARDS. However, each of them has limitations. Notably, oleic acid (OA) is increased in critically ill patients with harmful effects on the lung. OA can induce lung injury by emboli, disrupting tissue, altering pH, and impairing edema clearance. OA-induced lung injury model resembles various features of ARDS with endothelial injury, increased alveolar permeability, inflammation, membrane hyaline formation, and cell death. Herein, induction of lung injury is described by injecting OA (in salt form) directly into the lung and intravenously in a mouse since it is the physiological form of OA at pH 7. Thus, the injection of OA in the salt form is a helpful animal model to study lung injury/ARDS without causing emboli or altering the pH, thereby getting close to what is happening in critically ill patients.

Procedure

Acute respiratory distress syndrome (ARDS) is a significant threat to critically ill patients with a high fatality rate. Pollutant exposure, cigarette smoke, infectious agents, and fatty acids can induce ARDS. Animal models can mimic the complex pathomechanism of the ARDS. However, each of them has limitations. Notably, oleic acid (OA) is increased in critically ill patients with harmful effects on the lung. OA can induce lung injury by emboli, disrupting tissue, altering pH, and impairing edema clearance. OA-induced lung injury model resembles various features of ARDS with endothelial injury, increased alveolar permeability, inflammation, membrane hyaline formation, and cell death. Herein, induction of lung injury is described by injecting OA (in salt form) directly into the lung and intravenously in a mouse since it is the physiological form of OA at pH 7. Thus, the injection of OA in the salt form is a helpful animal model to study lung injury/ARDS without causing emboli or altering the pH, thereby getting close to what is happening in critically ill patients.

Tags